Imprimis Pharmaceuticals Inc., of San Diego, said it will conduct a proposed underwritten public offering of its common stock, subject to market and other conditions, and also intends to grant the underwriters the option to purchase additional shares equal to up to 15 percent of the aggregate number of shares sold in the offering to cover overallotments.